2024
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Maxwell M, Hom-Tedla M, Yi J, Li S, Rivera S, Yu J, Burns M, McRae H, Stevenson B, Coakley K, Ho J, Gastelum K, Bell J, Jones A, Eskander R, Dykhuizen E, Shadel G, Kaech S, Hargreaves D. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell 2024, 187: 3390-3408.e19. PMID: 38754421, PMCID: PMC11193641, DOI: 10.1016/j.cell.2024.04.025.Peer-Reviewed Original ResearchImmune checkpoint blockadeAnti-tumor immunityIncreased CD8+ T cell infiltrationCD8+ T cell infiltrationT cell infiltrationType I IFN signalingGene expression signaturesICB treatmentCheckpoint blockadeIndependent of microsatellite instabilityARID1A mutationsCytolytic activityImmune phenotypeMurine modelCell infiltrationARID1A lossClinical trialsMutant cancersARID1AHuman cancersExpression signaturesGene upregulationMicrosatellite instabilityCancerInterferonAbstract P28: Comprehensive Molecular Phenotyping of ARID1A -deficient Gastric Cancer Reveals Pervasive Epigenomic Reprogramming and Therapeutic Opportunities
Xu C, Huang K, Law J, Chua J, Sheng T, Flores N, Pizzi M, Okabe A, Tan A, Zhu F, Kumar V, Lu X, Benitez A, Lian B, Ma H, Ho S, Ramnarayanan K, Anene-Nzelu C, Razavi-Mohseni M, Ghani S, Tay S, Ong X, Lee M, Guo Y, Ashktorab H, Smoot D, Li S, Skanderup A, Beer M, Foo R, Wong J, Sanghvi K, Yong W, Sundar R, Kaneda A, Prabhakar S, Mazur P, Ajani J, Yeoh K, So J, Tan P. Abstract P28: Comprehensive Molecular Phenotyping of ARID1A -deficient Gastric Cancer Reveals Pervasive Epigenomic Reprogramming and Therapeutic Opportunities. Cancer Research 2024, 84: p28-p28. DOI: 10.1158/1538-7445.fcs2023-p28.Peer-Reviewed Original ResearchGastric cancerMolecular subtypesARID1A lossPro-inflammatory tumor microenvironmentTherapeutic opportunitiesARID1A inactivationTumor microenvironmental changesEpigenomic reprogrammingMutational signaturesPromoter activityGastric cell linesARID1A depletionTumor-intrinsicTumor inflammationTumor microenvironmentSingle-cell transcriptome profilingMutated driver genesTherapeutic vulnerabilitiesGC molecular subtypesNFkB inhibitorARID1ATherapeutic strategiesPharmacological inhibitionGC patientsSingapore cohort
2016
ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance
Lee L, Sadot E, Ivelja S, Vakiani E, Hechtman J, Sevinsky C, Klimstra D, Ginty F, Shia J. ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Human Pathology 2016, 53: 97-104. PMID: 26980037, PMCID: PMC4994515, DOI: 10.1016/j.humpath.2016.02.004.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCell DifferentiationColorectal NeoplasmsDisease ProgressionDisease-Free SurvivalDNA Mismatch RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNuclear ProteinsProportional Hazards ModelsRetrospective StudiesTime FactorsTissue Array AnalysisTranscription FactorsTreatment OutcomeYoung AdultConceptsColorectal carcinomaPrognostic significanceARID1A lossARID1A expressionPrognostic value of ARID1AEarly stage CRC patientsRecurrence-free survivalMedian Follow-UpAssociated with female sexStage CRC patientsChromatin remodeling genesLoss of ARID1AHeterogeneous patient populationLymphovascular invasionCurative intentPT stageAdjuvant therapyRetrospective seriesMismatch repair protein deficiencyPrognostic valueTissue microarrayEarly stage CRCPrognostic markerCRC patientsAnalyzed tumors
2014
Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage
Ye J, Zhou Y, Weiser M, Gönen M, Zhang L, Samdani T, Bacares R, DeLair D, Ivelja S, Vakiani E, Klimstra D, Soslow R, Shia J. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Human Pathology 2014, 45: 2430-2436. PMID: 25311944, DOI: 10.1016/j.humpath.2014.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdolescentAdultAgedAged, 80 and overCarcinoma, MedullaryColorectal NeoplasmsDNA MethylationDNA Mismatch RepairDNA-Binding ProteinsFemaleHumansImmunohistochemistryMaleMicrosatellite InstabilityMiddle AgedMutL Protein Homolog 1Neoplasm StagingNuclear ProteinsPilot ProjectsPromoter Regions, GeneticTranscription FactorsYoung AdultConceptsMicrosatellite unstable colorectal carcinomasLynch syndrome screeningMMR-deficient casesMedullary histologyMismatch repairMMR-deficient tumorsColorectal carcinomaDNA mismatch repairSyndrome screeningOlder agePilot studyAssociationARID1A lossOvarian cancerLoss of stainingIncreased rateConsecutive seriesMicrosatellite unstable tumorsChromatin remodeling genesMLH1Lynch
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply